GSK Cambridge Research Campus: What Could It Mean for Life Sciences?

[Campus reveiw]

GSK's announcement of a new flagship R&D centre at Cambridge Biomedical Campus has generated interest across the UK's pharmaceutical and life-sciences sector.

The planned centre will cover approximately 300,000 square feet and is expected to accommodate more than 1,000 scientists. GSK has committed £400 million over three years to support the changes to its UK R&D network.

The Cambridge location is significant because it brings GSK closer to a major ecosystem of universities, hospitals, biomedical researchers and biotechnology organisations. GSK says this environment can help accelerate collaboration and medicine development.

Research at the new centre will cover areas including:

Oncology
Respiratory diseases
Hepatology
Vaccines
HIV

The move also includes the planned closure of GSK's Stevenage R&D site by 2029 and upgrades to its Ware laboratories.

For students and researchers, the development raises interesting questions about the future of UK pharmaceutical R&D, life-science careers and biomedical innovation.

📖 Read more:
https://thecampusreview.com/news/gsk-cambridge-research-campus/

#GSK #CambridgeResearch #LifeSciences #PharmaceuticalResearch #Biotechnology #RAndD #DrugDiscovery #Healthcare